DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Raised to $16.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective increased by Mizuho from $14.00 to $16.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.

Several other research firms have also commented on XRAY. Zacks Research lowered DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. JPMorgan Chase & Co. dropped their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Wells Fargo & Company boosted their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price target for the stock from $13.00 to $17.00 in a report on Thursday, February 19th. Finally, Stifel Nicolaus set a $13.00 price objective on shares of DENTSPLY SIRONA in a report on Thursday, November 6th. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $14.42.

DENTSPLY SIRONA Stock Up 1.1%

NASDAQ:XRAY opened at $13.44 on Monday. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The company’s fifty day moving average price is $12.56 and its 200-day moving average price is $12.48. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.18. The firm has a market capitalization of $2.68 billion, a P/E ratio of -4.48, a PEG ratio of 1.56 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. DENTSPLY SIRONA’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts anticipate that DENTSPLY SIRONA will post 1.84 EPS for the current year.

DENTSPLY SIRONA Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is currently -21.33%.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 22,445 shares of the stock in a transaction on Tuesday, March 3rd. The shares were bought at an average price of $14.03 per share, with a total value of $314,903.35. Following the purchase, the director directly owned 50,000 shares in the company, valued at $701,500. This trade represents a 81.46% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently modified their holdings of XRAY. Eurizon Capital SGR S.p.A. acquired a new position in DENTSPLY SIRONA during the fourth quarter worth about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in DENTSPLY SIRONA in the 1st quarter worth approximately $26,000. Parkside Financial Bank & Trust boosted its holdings in shares of DENTSPLY SIRONA by 620.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 1,477 shares during the last quarter. Huntington National Bank boosted its holdings in shares of DENTSPLY SIRONA by 292.9% during the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,077 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director purchases: Long‑time director Gregory T. Lucier bought sizable blocks of stock on March 2 and March 3 (27,555 shares at ~$14.24 and 22,445 shares at ~$14.03), raising his ownership to ~50,000 shares — a strong insider confidence signal. InsiderTrades Article
• Positive Sentiment: Barrington Research raised its price target to $17 — an upbeat analyst action that implies meaningful upside relative to current levels and can attract buyer interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a negative rating and potentially supporting short‑term sentiment improvement. Zacks Upgrade
• Neutral Sentiment: Mizuho raised its price target to $16 but left a “neutral” rating — modestly positive for price targets but limited catalyst without a rating upgrade. Mizuho Note
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference (Mar 10) — a scheduled event that could provide fresh guidance or color but is not itself a guaranteed catalyst. Conference Notice
• Neutral Sentiment: Fundamental watch‑items: Coverage notes flag international revenue trends and mixed analyst targets (average PT ~$14.42) — useful context for modeling but neither clearly bullish nor bearish on its own. Zacks Analysis
• Neutral Sentiment: Short‑interest reporting appears anomalous (reports showing zero/NaN), so treat any short‑squeeze narratives as unreliable until corrected data is posted.
• Negative Sentiment: Earnings & guidance caveat: The company slightly missed quarterly EPS consensus (by ~$0.01) despite a revenue beat, and FY‑2026 guidance (1.40–1.50 EPS) sits below some sell‑side estimates (~1.84), which could cap upside if analysts lower forecasts. MarketBeat Summary

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.